In an animal model of HF, the administration of fenofibrate, a PPARα agonist, led to a reduction in the levels of brain natriuretic peptide (BNP) and ROS production [28]; the treatment also showed an increase in the oxidation of FA [29]. This evidence concerns the gene NPPB and hydrops fetalis.